Project Grant R21AI189231
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$454K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $131,268 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University (GWU). The grant supports research to evaluate the role of the PTPN1 and PTPN2 phosphatases in regulating natural killer (NK) cell function against HIV. The project aims to assess the impact of inhibiting these phosphatases, either pharmacologically or through CRISPR gene editing, on enhancing...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $486,057 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The 5-year grant, awarded on June 6, 2025, will support the development of a multipronged mRNA gene therapy approach to address HIV persistence and enable a potential cure. The proposed research aims...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,564,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The project will run from August 2024 through June 2029. The grant supports several key products and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $673,158 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a proteomics atlas of HIV/HBV co-infections for advancing HBV cure strategies. The project aims to use robust co-culture systems, CRISPR screens, and multi-omics approaches in primary human hepatocytes and CD4+ T cells to discover and validate host factors and antivirals against HIV/HBV...
This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
This $760,038 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by George Mason University to study the anti-HIV properties of the PSGL-1 protein, a newly identified HIV restriction factor. The research aims to determine the structure-function relationship of the PSGL-1 DR domain and its impact on anti-HIV activity through a combination of...